Evidence map›Paper›PMID 35628574›Full record

ArticleInternational journal of molecular sciences2022

Pathways Related to NLRP3 Inflammasome Activation Induced by Gold Nanorods.

Rob J Vandebriel, Sylvie Remy, Jolanda P Vermeulen, Evelien G E Hurkmans, Kirsten Kevenaar, Neus G Bastús, Beatriz Pelaz, Mahmoud G Soliman, Victor F Puntes, Wolfgang J Parak and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rob J VandebrielCentre for Health Protection, National Institute for Public Health & the Environment, 3720 BA Bilthoven, The Netherlands.ORCID 0000-0001-9140-952X
Sylvie RemyHealth Unit, VITO NV, 2400 Mol, Belgium.ORCID 0000-0003-0322-9620
Jolanda P VermeulenCentre for Health Protection, National Institute for Public Health & the Environment, 3720 BA Bilthoven, The Netherlands.
Evelien G E HurkmansCentre for Health Protection, National Institute for Public Health & the Environment, 3720 BA Bilthoven, The Netherlands.ORCID 0000-0002-1333-1496
Kirsten KevenaarCentre for Health Protection, National Institute for Public Health & the Environment, 3720 BA Bilthoven, The Netherlands.ORCID 0000-0002-4050-1825
Neus G BastúsInstitut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.ORCID 0000-0002-3144-7986
Beatriz PelazCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, 15782 Santiago, Spain.
Mahmoud G SolimanFachbereich Physik, CHyN, University of Hamburg, 22761 Hamburg, Germany.
Victor F PuntesInstitut Català de Nanociència i Nanotecnologia (ICN2), Consejo Superior de Investigaciones Científicas (CSIC), The Barcelona Institute of Science and Technology (BIST), Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Wolfgang J ParakFachbereich Physik, CHyN, University of Hamburg, 22761 Hamburg, Germany.ORCID 0000-0003-1672-6650
Jeroen L A PenningsCentre for Health Protection, National Institute for Public Health & the Environment, 3720 BA Bilthoven, The Netherlands.ORCID 0000-0002-9188-6358
Inge NelissenHealth Unit, VITO NV, 2400 Mol, Belgium.ORCID 0000-0002-1248-3463

Funding

European Union 604602Flemish Institute for Technological Research N/ANational Institute for Public Health and the Environment N/A
6 · The paper itself

Abstract

The widespread and increasing use of engineered nanomaterials (ENM) increases the risk of human exposure, generating concern that ENM may provoke adverse health effects. In this respect, their physicochemical characteristics are critical. The immune system may respond to ENM through inflammatory reactions. The NLRP3 inflammasome responds to a wide range of ENM, and its activation is associated with various inflammatory diseases. Recently, anisotropic ENM have become of increasing interest, but knowledge of their effects on the immune system is still limited. The objective of the study was to compare the effects of gold ENM of different shapes on NLRP3 inflammasome activation and related signalling pathways. Differentiated THP-1 cells (wildtype, ASC- or NLRP3-deficient), were exposed to PEGylated gold nanorods, nanostars, and nanospheres, and, thus, also different surface chemistries, to assess NLRP3 inflammasome activation. Next, the exposed cells were subjected to gene expression analysis. Nanorods, but not nanostars or nanospheres, showed NLRP3 inflammasome activation. ASC- or NLRP3-deficient cells did not show this effect. Gene Set Enrichment Analysis revealed that gold nanorod-induced NLRP3 inflammasome activation was accompanied by downregulated sterol/cholesterol biosynthesis, oxidative phosphorylation, and purinergic receptor signalling. At the level of individual genes, downregulation of Paraoxonase-2, a protein that controls oxidative stress, was most notable. In conclusion, the shape and surface chemistry of gold nanoparticles determine NLRP3 inflammasome activation. Future studies should include particle uptake and intracellular localization.

Indexed as

GoldMetal NanoparticlesNanotubesNLR Family, Pyrin Domain-Containing 3 ProteinHumansInflammasomesGoldInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humancholesterolgoldinflammationnanorodnanospherenanostarNLRP3oxidative phosphorylationparaoxonase-2purinergic receptor

Identifiers

PMID35628574
PMCPMC9145314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.